D-Pharm Successfully Completed Phase IIb Trial of its Neuroprotective Compound (DP-b99) in Acute Stroke Patients
D-Pharm’s DP-b99 is a unique neuroprotective drug that addresses an array of damaging processes occurring in the brains of stroke patients.
As recently announced by D-Pharm (691243), the Phase IIb trial of the neuroprotective compound has been successfully completed.
A significantly higher recovery rate after stroke was found in the DP-b99 treatment group compared to the placebo group. The study also confirmed the excellent safety and tolerability profile of DP-b99.
There was no difference in response to DP-b99 treatment between those patients treated within six hours or within six to nine hours following stroke onset confirming the wide therapeutic treatment window for DP-b99.
DP-b99 is a new chemical entity developed from D-Pharm's proprietary platform technology Membrane Active Chelators (MAC), a first in class neuroprotective compound, membrane activated lipophilic chelator of zinc, copper and calcium ions.
Find more details from the press release.
Comment Preview